Polycomb Genes are Associated with Response to Imatinib in Chronic Myeloid Leukemia

References

• Sacha T . Imatinib in chronic myeloid leukemia: an overview . Mediterr. J. Hematol. Infect. Dis.6 ( 1 ), e2014007 ( 2014 ).
   PubMedGoogle Scholar
• O’brien SG , GuilhotF , LarsonRAet al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia . N. Engl. J. Med.348 ( 11 ), 994 – 1004 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Druker BJ , GuilhotF , O’brienSGet al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia . N. Engl. J. Med.355 ( 23 ), 2408 – 2417 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A , CortesJE , KantarjianHM . Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications . Cancer117 ( 23 ), 5261 – 5270 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Francis S , LucasC , LaneSet al. A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia . Leuk. Res.37 ( 7 ), 752 – 758 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Dulucq S , KrajinovicM . The pharmacogenetics of imanitib . Genome Med.2 ( 11 ), 85 ( 2010 ).
   PubMedGoogle Scholar
• Di Paolo A , PolilloM , CapecchiMet al. The c.480c>g polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia . Pharmacogenomics J.14 ( 4 ), 328 – 335 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Crea F , DanesiR , FarrarWL . Cancer stem cell epigenetics and chemoresistance . Epigenomics1 ( 1 ), 63 – 79 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Crea F , PaolicchiE , MarquezVE , DanesiR . Polycomb genes and cancer: time for clinical application?Crit. Rev. Oncol. Hematol.83 ( 2 ), 184 – 193 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Guo WJ , ZengMS , YadavAet al. Mel-18 acts as a tumor suppressor by repressing BMI-1 expression and down-regulating Akt activity in breast cancer cells . Cancer Res.67 ( 11 ), 5083 – 5089 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Crea F , Duhagon SerratMA , HurtEM , ThomasSB , DanesiR , FarrarWL . BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer . Int. J. Cancer128 ( 8 ), 1946 – 1954 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Mohty M , YongAS , SzydloRM , ApperleyJF , MeloJV . The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia . Blood110 ( 1 ), 380 – 383 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Bhattacharyya J , MiharaK , YasunagaSet al. BMI-1 expression is enhanced through transcriptional and post-transcriptional regulation during the progression of chronic myeloid leukemia . Ann. Hematol.88 ( 4 ), 333 – 340 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Hirano A , MoriH , SawaiH . Uranyl ion-catalyzed synthesis of several 8-substituted 2′-5′-oligoadenylates, and their properties . Nucleic Acids Symp. Ser. ( 22 ), 15 – 16 ( 1990 ).
   PubMedGoogle Scholar
• Clinical Trials Database: NCT01860456 . https://clinicaltrials.gov/ct2/show/NCT01860456 .
   Google Scholar
• Crea F , WatahikiA , QuagliataLet al. Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer . Oncotarget5 ( 3 ), 764 – 774 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Soverini S , HochhausA , NicoliniFEet al. BCR–ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European leukemianet . Blood118 ( 5 ), 1208 – 1215 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Youden WJ . Index for rating diagnostic tests . Cancer3 ( 1 ), 32 – 35 ( 1950 ).
   PubMed Web of Science ®Google Scholar
• Rhodes DR , YuJ , ShankerKet al. Oncomine: a cancer microarray database and integrated data-mining platform . Neoplasia6 ( 1 ), 1 – 6 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Papadopoulou LC , KyriazouAV , BonovoliasID , TsiftsoglouAS . Imatinib inhibits the expression of SCO2 and frataxin genes that encode mitochondrial proteins in human BCR–ABL(+) leukemia cells . Blood Cells Mol. Dis.53 ( 1–2 ), 84 – 90 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Bracken AP , DietrichN , PasiniD , HansenKH , HelinK . Genome-wide mapping of polycomb target genes unravels their roles in cell fate transitions . Genes Dev.20 ( 9 ), 1123 – 1136 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Nor C , ZhangZ , WarnerKAet al. Cisplatin induces BMI-1 and enhances the stem cell fraction in head and neck cancer . Neoplasia16 ( 2 ), 137 – 146 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Morey L , PascualG , CozzutoLet al. Nonoverlapping functions of the polycomb group CBX family of proteins in embryonic stem cells . Cell Stem Cell10 ( 1 ), 47 – 62 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Li G , WardenC , ZouZet al. Altered expression of polycomb group genes in glioblastoma multiforme . PLoS ONE8 ( 11 ), e80970 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Forzati F , FedericoA , PallantePet al. CBX7 is a tumor suppressor in mice and humans . J. Clin. Invest.122 ( 2 ), 612 – 623 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Naveau S , MoryB , PoynardT , ChaputJC . Randomized therapeutic trials in intestinal functional disorders . Gastroenterol. Clin. Biol.14 ( 5 Pt. 2 ), C65 – C73 ( 1990 ).
   Google Scholar
• Saudy NS , FawzyIM , AzmyE , GodaEF , EneenA , Abdul SalamEM . BMI1 gene expression in myeloid leukemias and its impact on prognosis . Blood Cells Mol. Dis.53 ( 4 ), 194 – 198 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Rizo A , HortonSJ , OlthofSet al. BMI1 collaborates with BCR–ABL in leukemic transformation of human CD34+ cells . Blood116 ( 22 ), 4621 – 4630 ( 2010 ).
   PubMed Web of Science ®Google Scholar